Tweet SAN FRANCISCO, CA, Epirium Bio today announced it has raised $85 million in Series A financing.

To export Epirium Bio funding data to PDF and Excel, clickClick here for more funding data on Epirium BioTo export Epirium Bio funding data to PDF and Excel, click here Epirium Bio, ("Epirium") formerly, Cardero Therapeutics, Inc., today announced it has raised $85 million in Series A financing provided by Longitude Capital, ARCH Venture Partners, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, and The Longevity Fund.

Epirium is a clinical stage biopharmaceutical company developing therapeutics that optimize both tissue bioenergetics and structure through a novel mechanism of action discovered by the company.

Epirium scientists have discovered a previously unknown hormonal pathway that appears to be an endogenous modulator of mitochondrial biogenesis - the formation of new mitochondria.

Epirium is headed by a seasoned team of industry veterans with decades of experience building and leading clinical and commercial stage companies. | To read full story, visit https://startuparound.com/read/1576785609.3800244/Epirium-Bio-Scores-$85M-Series-A?ref=audio_experience